6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications

2:

• The 6,8-disubstituted-9-(heterocyclyl)purines of claim 1, wherein Ry is selected from the group consisting of furfuryl, phenyl, benzyl, 3-methylbut-2-en-1-yl, cyclohexylmethyl, allyl or 3,3-dimethylallyl, wherein each of these substituents can optionally be substituted with one or more substitutents selected from halogen, hydroxy, methoxy, methyl, amino, nitro or combinations thereof.

3:

• The 6,8-disubstituted-9-(heterocyclyl)purines of claim 1, wherein R8 is selected from the group consisting of amino, alkylamino, hydroxy, chloro, fluoro, bromo, amino(C1-C5 alkyl)amino, hydroxy(C1-C5 alkyl)amino, NHOH, NHNH2, carboxyl, nitro, sulphanyl, methylsulphanyl, methoxy.

5:

• The 6,8-disubstituted-9-(heterocyclyl)purines according to claim 1 for use as antioxidants in plants, mammals or humans, in particular for use as antioxidants for inhibiting lipid pre-oxidation in plants, mammals or humans.

6:

• The 6,8-disubstituted-9-(heterocyclyl)purines according to claim 1 for use as medicaments.

7:

• The 6,8-disubstituted-9-(heterocyclyl)purines according to claim 1 for use in a method of treatment of skin conditions such as acne, erythema and redness, as antineurodegenerative drugs, in methods of suppression of immunostimulation, in a method of treatment of inflammation.

8:

• Use of the 6,8-disubstituted-9-(heterocyclyl)purines according to claim 1 as cosmetics.

9:

• Use of the 6,8-disubstituted-9-(heterocyclyl)purines according to claim 1 as cosmetics in inhibition, delaying, or reducing the adverse effects of aging and senescence, and for improving the overall appearance and condition of the skin.

10:

• Use of the 6,8-disubstituted-9-(heterocyclyl)purines according to claim 1 as growth regulators in tissue cultures for stimulation of proliferation, morphogenesis and senescence;
• as cell division and differentiation factors of plant, mammal, microorganisms, yeast and fungal cells.

11:

• Use of the 6,8-disubstituted-9-(heterocyclyl)purines according to claim 1 for preparation of affinity absorption matrices, immobilised enzymes for process control, immunoassay reagents, diagnostic samples, as well as compounds and oligonucleotides, labelled by 14C, 3H, avidin, biotin;
• for use with plant and mammalian (non-human) embryonic stem cells and embryo cloning.

12:

• A method for ameliorating the adverse effects of aging in mammalian and plant cells, said method comprising administering at least one 6,8-disubstituted-9-(heterocyclyl)purine according to claim 1, to the mammalian cells or tissue in an amount effective to ameliorate the adverse effects of aging in the cells.

13:

• Pharmaceutical and/or cosmetic composition comprising one or more 6,8-disubstituted-9-(heterocyclyl)purine of the formula I according to claim 1 and at least one auxiliary substance.